Long Island’s Precision Medicine Steps Back From Compounded GLP-1s

For two years, compounded GLP-1 medications were the busiest corner of telehealth. Semaglutide and tirzepatide, the active ingredients in Ozempic, Wegovy, Mounjaro and Zepbound, were on the FDA’s drug shortage list, and federal rules allowed compounding pharmacies to make their own versions while supply was short. Online weight-loss brands multiplied, and many of the pharmacies behind them reorganized around a single drug class.

Precision Medicine, a 503A pharmacy headquartered in Bellmore on Long Island’s South Shore, made a different call. The company says it is stepping back from compounded GLP-1s to build lasting infrastructure around sermorelin, hormone health and long-term compliance. Its own summary of the decision is short: “While much of the market raced toward GLP-1s, we kept building somewhere quieter.”

Why the rush was always temporary

The legal basis for mass compounding of GLP-1s was the shortage itself. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. Once a drug is off the shortage list, a 503A pharmacy generally cannot compound what is essentially a copy of a commercially available product. Pharmacies built on that one category faced a sudden question about what came next.

Precision Medicine still handles commercial, non-compounded GLP-1 medications for its telehealth partners, according to its website. What it has moved away from is building its business on the compounded versions.

Sterile preparations are compounded under USP chapter 797. Image: Precision Medicine.
Sterile preparations are compounded under USP chapter 797. Image: Precision Medicine.

Where it is putting its effort

The company’s formulary now leans on categories where compounding has a longer history: bioidentical hormone therapy, peptide preparations such as sermorelin, men’s and women’s health, and longevity medicine. Its weight-management work is grouped under metabolic support, appetite and craving control, energy and performance, and nutrient optimization.

It is also spending on compliance and capacity. Precision Medicine says it holds licenses in 49 states, is accredited by the National Association of Boards of Pharmacy and certified by LegitScript, and follows USP chapters 795, 797 and 800. It runs hubs in Bellmore and in Boca Raton, Florida, and operates a sterile compounding facility in California.

The bigger signal

For patients, the practical point is that compounded medications are not FDA-approved, and the FDA does not review them for safety, effectiveness or quality before they reach patients. That places the weight on the pharmacy’s licenses, standards and inspection record, and on a prescriber deciding whether a compounded preparation is appropriate at all.

For the industry, Precision Medicine’s choice is a bet that the durable part of telehealth pharmacy is not any one drug. It is the regulated, unglamorous work of filling prescriptions correctly in every state a patient lives in, long after a single category stops making headlines.

Back To Top